August 23, 2018
The Ministry of Health, Labor and Welfare (MHLW) will issue “optimal use promotion guidelines” for AstraZeneca’s anti-PD-L1 antibody Imfinzi (durvalumab), which will join the NHI price list on August 29. The guidelines, which strictly define the scope of eligible patients...read more